成人肺炎球菌疫苗 uptake 提升项目的进一步研究是否值得?一项信息价值分析
该研究采用信息价值(VOI)分析,评估在美国50-64岁及≥65岁成人中进一步研究肺炎球菌疫苗 uptake 提升项目参数的价值。结果显示,在常用成本效果阈值下,VOI 结果不支持对成人肺炎球菌疫苗 uptake 项目开展进一步研究,而减少其他模型参数不确定性的研究更具价值。
要点
- 在50-64岁成人中, uptake 项目相比无项目每获得一个QALY需花费54,900美元。
- 在≥65岁成人中,替代策略下 uptake 项目每QALY花费287,000美元,当前推荐下为765,000美元。
- 在常用美国成本效果基准下,VOI结果不支持进一步研究成人肺炎球菌疫苗 uptake 项目。
核心结论
- VOI结果不支持在常用美国成本效果基准下对成人肺炎球菌疫苗 uptake 项目开展进一步研究。
- 减少成人肺炎球菌疫苗接种其他方面不确定性的进一步研究具有合理性。
研究设计与样本
- 研究对美国50-64岁及≥65岁成人进行成本效果与信息价值分析。
- uptake 项目参数来自一项临床试验:绝对 uptake 增加12.3%(范围0-25%),每人成本1.78美元(范围0.70-2.26美元)。
- 其他参数来自美国数据库,VOI分析将概率敏感性分析输出纳入基于R的回归技术。
主要发现
- 在50-64岁成人中, uptake 项目相比无项目每获得一个QALY花费54,900美元。
- 在≥65岁成人中,替代策略下 uptake 项目每QALY花费287,000美元,当前推荐下为765,000美元。
- 年轻人群中 uptake 项目成本与 uptake 改善参数联合的人群部分完美信息期望价值(EVPPI)在50,000美元/QALY阈值为368,700美元,在100,000美元/QALY阈值为43,900美元。
临床怎么用
- 在决策是否资助成人肺炎球菌疫苗 uptake 提升项目时,可参考其成本效果与VOI分析结果。
- 在常用美国成本效果基准下,优先支持减少其他模型参数不确定性的研究而非 uptake 项目参数研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcal vaccination policy for US adults is evolving, but previous research has shown that programs to increase vaccine uptake are economically favorable, despite parameter uncertainty. Using value of information (VOI) analysis and prior analyses, we examine the value of further research on vaccine uptake program parameters. METHODS: In US 50-64-year-olds, current vaccine recommendations with and without an uptake program were analyzed. In older adults, current recommendations and an alternative strategy (polysaccharide vaccine for all, adding conjugate vaccine only for the immunocompromised) with and without uptake programs were examined. Uptake program parameters were derived from a clinical trial (absolute uptake increase 12.3% [range 0-25%], per-person cost $1.78 [range $0.70-$2.26]), with other parameters obtained from US databases. VOI analyses incorporated probabilistic sensitivity analysis outputs into R-based regression techniques. RESULTS: In 50-64-year-olds, an uptake program cost $54,900/QALY gained compared to no uptake program. For ages ≥65, the program cost $287,000/QALY gained with the alternative strategy and $765,000/QALY with current recommendations. In younger adults, population-level expected value of perfect information (EVPI) was $59.7 million at $50,000/QALY gained and $2.8 million at $100,000/QALY gained. In older adults, EVPI values ranged from ~$1 million to $34.5 million at $100,000 and $200,000/QALY thresholds. The population expected value of partial perfect information (EVPPI) for combined uptake program cost and uptake improvement parameters in the younger population was $368,700 at $50,000/QALY and $43,900 at $100,000/QALY gained thresholds. In older adults, population EVPPI for vaccine uptake program parameters was $0 at both thresholds, reaching a maximum value of $445,000 at a $225,000/QALY threshold. Other model parameters comprised larger components of the global EVPI. CONCLUSION: VOI results do not support further research on pneumococcal vaccine uptake programs in adults at commonly cited US cost-effectiveness benchmarks. Further research to reduce uncertainty in other aspects of adult pneumococcal vaccination is justifiable.
引用
- Wateska AR, Nowalk MP, Jalal H, et al. Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Α value of information analysis. Vaccine. 2021. PMID: 34045104. doi:10.1016/j.vaccine.2021.05.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。